Human papillomaviruses: General features

Clinics in Dermatology

Volumn 15, Issue 2, 1997, Pages 181-198

  Favre, Michel ^a   Ramoz, Nicolas ^a   Orth, Gérard ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HOST SUSCEPTIBILITY; HUMAN; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; REVIEW; SKIN CARCINOMA; UTERINE CERVIX CARCINOMA; VIRION; VIRUS CARCINOGENESIS; VIRUS CLASSIFICATION; VIRUS EXPRESSION; VIRUS GENE; VIRUS GENOME; WART VIRUS;

EID: 0030913830     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(97)00008-4     Document Type: Article

References (164)

1. Orth G. Human papillomaviruses: general features. In: Webster RG, Granhoff A, editors. Encyclopedia of virology, vol. 2. London: Academic Press, 1994:1013-21.
2. Zur Hausen H. Papillomavirus infections: a major cause of human cancers. Biochim Biophys Acta 1996;1288:F55-F78.
3. Howley PM. Papillomaviridae: the viruses and their replication. In: Fields BN, Knipe DM, Howley PM, editors. Virology, vol. 2. Philadelphia: Lippincott-Raven, 1996: 2045-76.
4. Rowson KE, Mahy BW. Human papova (wart) virus. Bacteriol Rev 1967;31:110-311.
5. Favre M, Orth G, Croissant O, et al. Human papillomavirus DNA: physical map. Proc Natl Acad Sci USA 1975; 72:4810-4.
6. Gissmann L, zur Hausen H. Human papilloma viruses: physical mapping and genetic heterogeneity. Proc Natl Acad Sci USA 1976;73:1310-3.
7. Gissmann L, Pfister H, zur Hausen H. Human papilloma viruses (HPV): characterization of four different isolates. Virology 1977;76:569-80.
8. Orth G, Favre M, Croissant O. Characterization of a new type of human papillomavirus that causes skin warts. J Virol 1977;24:108-20.
9. Orth G, Jablonska S, Favre M, et al. Characterization of two types of human papillomaviruses in lesions of epidermodysplasia verruciformis. Proc Natl Acad Sci USA 1978;75:1537-41.
10. Orth G, Favre M, Jablonska S, et al. Viral sequences related to a human skin papillomavirus in genital warts. Nature 1978;275:334-6.
11. Orth G, Jablonska S, Breitburd F, et al. The human papillomaviruses. Bull Cancer 1978;65:151-64.
12. Orth G. Epidermodysplasia verruciformis. In: Howley PM, Salzman NP, editors. The papillomaviruses. vol. 2. New York: Plenum Press, 1987:199-243.
13. Shamanin V, zur Hausen H, Lavergne D, et al. Human papillomavirus infections in nonmelanoma skin cancers from renal transplant recipients and nonimmunosuppressed patients. J Nat Cancer Inst 1996;88:802-11.
14. Berkhout RJM, Tieben LM, Smits HL, et al. Nested PCR approach for detection and typing of epidermodysplasia verruciformis-associated human papillomavirus types in cutaneous cancers from renal transplant recipients. J Clin Microbiol 1995;33:690-5.
15. Pfister H, Fuchs PG. Anatomy, taxonomy and evolution of papillomaviruses. Intervirology 1994;37:143-9.
16. Belnap DM, Olson NH, Cladel NM, et al. Conserved features in papillomavirus and polyomavirus capsids. J Mol Biol 1996;259:249-63.
17. Zhou J, Frazer IH. Papovaviridae: capsid structure and capsid protein function. Papillomavirus Rep 1995;6:59-64.
18. Favre M, Breitburd F, Croissant O, et al. Structural polypeptides of rabbit, bovine, and human papillomaviruses. J Virol 1975;15:1239-47.
19. Favre M, Breitburd F, Croissant O, et al. Chromatin-like structure obtained after alkaline disruption of bovine and human papillomaviruses. J Virol 1977;21:1205-9.
20. Myers G, Baker C, Wheeler C, et al., editors. Human papillomaviruses 1996. A compilation and analysis of nucleic acid and amino acid sequences. Los Alamos, New Mexico: Los Alamos National Laboratory, 1996.
21. Fuchs PG, Pfister H. Papillomaviruses in epidermodysplasia verruciformis. In: Lacey C, editor. Papillomavirus reviews: Current research on papillomaviruses. Leeds: Leeds University Press, 1996:253-61.
22. Delius H, Van Ranst MA, Jenson AB, et al. Canine oral papillomavirus genomic sequence: a unique 1.5-kb intervening sequence between the E2 and L2 open reading frames. Virology 1994;204:447-52.
23. Manos MM, Ting Y, Wright DK, et al. The use of the polymerase chain reaction amplification for the detection of genital human papillomaviruses. Cancer Cells 1989;7: 209-14.
24. De Roda Husman A-M, Walboomers JMM, van den Brule AJC, et al. The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol 1995;76:1057-62.
25. Kawashima M, Favre M, Obalek S, et al. Premalignant lesions and cancers of the skin in the general population. Evaluation of the role of human papillomaviruses. J Invest Dermatol 1990;95:537-42.
26. Zur Hausen H, de Villiers EM. Human papillomaviruses. Annu Rev Microbiol 1994;48:427-47.
27. Deau M-C, Favre M, Jablonska S, et al. Genetic heterogeneity of oncogenic human papillomavirus type 5 (HPV5) and phylogeny of HPV5 variants associated with epidermodysplasia verruciformis. J Clin Microbiol 1993; 31:2918-26.
28. Bernard H-U, Chan S-Y, Manos MM, et al. Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence, and phylogenetic algorithms. J Infect Dis 1994; 170:1077-85.
29. Chan S-Y, Delius H, Halpern AL, et al. Analysis of genomic sequences of 95 papillomavirus types: uniting typing, phylogeny, and taxonomy. J Virol 1995;69:3074-83.
30. Van Ranst M, Kaplan JB, Burk RD. Phylogenetic classification of human papillomaviruses: correlation with clinical manifestations. J Gen Virol 1992;73:2653-60.
31. Icenogle JP, Sathya P, Miller DL, et al. Nucleotide and amino acid sequence variation in the L1 and E7 open reading frames of human papillomavirus type 6 and type 16. Virology 1991;184:101-7.
32. Stewart ACM, Eriksson AM, Manos MM, et al. Intratype variation in 12 human papillomavirus types: A worldwide perspective. J Virol 1996;70:3127-36.
33. Yamada T, Wheeler CM, Halpern AL, et al. Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments. J Virol 1995; 69:7743-53.
34. Chan S-Y, Ho L, Ong C-K, et al. Molecular variants of human papillomavirus type 16 from four continents suggest ancient pandemic spread of the virus and its coevolution with humankind. J Virol 1992;66:2057-66.
35. Deau M-C, Favre M, Orth G. Genetic heterogeneity among human papillomaviruses (HPVs) associated with epidermodysplasia verruciformis: Evidence for multiple allelic forms of HPV5 and HPV8 E6 genes. Virology 1991; 184:492-503.
36. Kawase M, Orth G, Jablonska S, et al. Variability and phylogeny of the L1 capsid protein gene of human papillomavirus type 5: contribution of clusters of nonsynonymous mutations and of a 30-nucleotide duplication. Virology 1996;221:189-98.
37. Stöppler MC, Ching K, Stöppler H, et al. Natural variants of the human papillomavirus type 16 E6 protein differ in their abilities to alter keratinocyte differentiation and to induce p53 degradation. J Virol 1996;70:6987-93.
38. Kirnbauer R, Taub J, Greenstone H, et al. Efficient self-assembly of human papillomavirus type-16 L1 and L1-L2 into virus-like particles. J Virol 1993;67:6929-36.
39. Grassmann K, Wilczynski SP, Cook N, et al. HPV6 variants from malignant tumors with sequence alterations in the regulatory region do not reveal differences in the activities of the oncogene promoters but do contain amino acid exchanges in the E6 and E7 proteins. Virology 1996;223:185-97.
40. Rübben A, Beaudenon S, Favre M, et al. Rearrangements of the upstream regulatory region of human papillomavirus type 6 can be found in both Buschke-Löwenstein tumours and in condylomata acuminata. J Gen Virol 1992;73:3147-53.
41. Roden RBS, Hubbert NL, Kirnbauer R, et al. Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J Virol 1996; 70:3298-301.
42. Christensen ND, Kirnbauer R, Schiller JT, et al. Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes. Virology 1994;205:329-35.
43. Ludmerer SW, Benincasa D, Mark GE III. Two amino acid residues confer type specificity to a neutralizing, conformationally dependent epitope on human papillomavirus type 11. J Virol 1996;70:4791-4.
44. Cheng G, Icenogle JP, Kirnbauer R, et al. Divergent human papillomavirus type 16 variants are serologically cross-reactive. J Infect Dis 1995;172:1584-7.
45. Orth G, Breitburd F, Favre M. Evidence for antigenic determinants shared by the structural polypeptides of (Shope) rabbit papillomavirus and human papillomavirus type 1. Virology 1978;91:243-55.
46. Jenson AB, Rosenthal JD, Olson C, et al. Immunologic relatedness of papillomaviruses from different species. J Natl Cancer Inst 1980;64:495-500.
47. Roden RBS, Kirnbauer R, Jenson AB, et al. Interaction of papillomaviruses with the cell surface. J Virol 1994;68: 7260-6.
48. Müller M, Gissmann L, Cristiano RJ, et al. Papillomavirus capsid binding and uptake by cells from different tissues and species. J Virol 1995;69:948-54.
49. O'Connor M, Chan S-Y, Bernard HU. Transcription factor binding sites in the long control region of genital HPVs. In: Myers G, Delius H, Icenogel J et al, editors. Human Papillomaviruses 1995. A compilation and analysis of nucleic acid and amino acid sequences. Los Alamos, New Mexico, USA: Los Alamos National Laboratory, 1995:III-21-III-40.
50. Kennedy IM, Haddow JK, Clements JB. A negative regulatory element in the human papillomavirus type 16 genome acts at the level of late mRNA stability. J Virol 1991;65:2093-7.
51. Thierry F. HPV proteins in the control of HPV transcription. In: Lacey C, editor. Papillomavirus reviews: Current research on papillomaviruses. Leeds: Leeds University Press, 1996:21-9.
52. Bernard HU, Apt D. Transcriptional control and cell type specificity of HPV gene expression. Arch Dermatol 1994; 130:210-5.
53. Yukawa K, Butz K, Yasui T, et al. Regulation of human papillomavirus transcription by the differention-dependent epithelial factor Epoc-1/skn-1a. J Virol 1996; 70:10-16.
54. Wettstein FO. State of viral DNA and gene expression in benign vs. malignant tumors. In: Pfister H, editor. Papillomaviruses and human cancer. Boca Raton: CRC Press, 1990:155-79.
55. Chow LT, Nasseri M, Wolinsky SM, et al. Human papillomavirus types 6 and 11 mRNAs from genital condylomata acuminata. J Virol 1987;61:2581-8.
56. Di Lorenzo TP, Steinberg BM. Differential regulation of human papillomavirus type 6 and 11 early promoters in cultured cells derived from laryngeal papillomas. J Virol 1995;69:6865-72.
57. Stubenrauch F, Malejczyk J, Fuchs P, et al. Late promotor of human papillomavirus type 8 and its regulation. J Virol 1992;66:6959-66.
58. Chow LT, Broker TR. Papillomavirus DNA replication. Intervirology 1994;37:150-8.
59. Park P, Copeland W, Yang L, et al. The cellular DNA polymerase α-primase is required for papillomavirus DNA replication and associates with the viral E1 heli-case. Proc Natl Acad Sci USA 1994;91:8700-4.
60. Farthing AJ, Vousden KH. Functions of human papillomavirus E6 and E7 oncoproteins. Trends Microbiol 1994; 2:170-4.
61. Münger K. The molecular biology of cervical cancer. J Cell Biochem 1995;23:55-60.
62. Keen N, Elston R, Crawford L. Interaction of the E6 protein of human papillomavirus with cellular proteins. Oncogene 1994;9:1493-9.
63. Chen JJ, Reid CE, Band V, et al. Interaction of papillomavirus E6 oncoproteins with a putative calcium-binding protein. Science 1995;269:529-31.
64. Heck DV, Yee CL, Howley PM, et al. Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses. Proc Natl Acad Sci 1992;89:4442-6.
65. Schmitt A, Harry JB, Rapp B, et al. Comparison of the properties of the E6 and E7 genes of low- and high-risk cutaneous papillomaviruses reveals strongly transforming and high Rb-binding activity for the E7 protein of the low-risk human papillomavirus type 1. J Virol 1994;68: 7051-9.
66. DiMaio D, Petti L, Hwang E-S. The E5 transforming proteins of the papillomaviruses. Semin Virol 1994;5:369-79.
67. Banks L, Matlashewski G. Biochemical and biological activities of the HPV E5 proteins. In: Lacey C, editor. Papillomavirus reviews: Current research on papillomaviruses. Leeds: Leeds University Press, 1996:39-15.
68. Doorbar J. The E4 proteins and their role in the viral life cycle. In: Lacey C, editor. Papillomavirus reviews: Current research on papillomaviruses. Leeds: Leeds University Press, 1996:31-8.
69. Rogel-Gaillard C, Pehau-Arnaudet G, Breitburd F, et al. Cytopathic effect in human papillomavirus type 1-induced inclusion warts: in vitro analysis of the contribution of two forms of the viral E4 protein. J Invest Dermatol 1993;101:843-51.
70. Croissant O, Breitburd F, Orth G. Specificity of cytopathic effect of cutaneous human papillomaviruses. Clin Dermatol 1985;3:43-55.
71. Roberts S, Ashmole I, Johnson GD, et al. Cutaneous and mucosal human papillomavirus E4 proteins form intermediate filament-like structures in epithelial cells. Virology 1993;197:176-87.
72. Zhou J, Frazer IH. Papovaviridiae: capsid structure and capsid protein function. In: Lacey C, editor. Papillomavirus reviews: Current research on papillomaviruses. Leeds: Leeds University Press, 1996:93-100.
73. Roden RBS, Greenstone HL, Kimbauer R, et al. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J Virol 1996; 70:5875-83.
74. Orth G, Favre M. Human papillomavirus: biochemical and biologic properties. Clin Dermatol 1985;3:27-42.
75. Shah KV, Howley PM. Papillomaviruses. In: Fields BN, Knipe DM, Howley PM, editors, Virology, vol. 2. Philadelphia: Lippincott-Raven, 1996:2077-109.
76. Breitburd F, Salmon J, Orth G. The rabbit viral skin papillomas and carcinomas, a model for the immunogenetics of HPV-associated carcinogenesis. Clin Dermatol 1997; 15(2): .
77. Campo S. Vaccination against papillomavirus in cattle. Clin Dermatol 1997;15:275-83.
78. Coussens LM, Hanahan D, Arbeit JM. Genetic predisposition and parameters of malignant progression in K14-HPV16 transgenic mice. Am J Pathol 1996;149:1899-917.
79. Ha-activated papillomas. Cell Growth Differ 1994;5:667-75.
80. Stoler MH, Wolinsky SM, Whitbeck A, et al. Differentiation-linked human papillomavirus types 6 and 11 transcription in genital condylomata revealed by in situ hybridization with message-specific RNA probes. Virology 1989;172:331-40.
81. Stoler MH, Rhodes CR, Whitbeck A, et al. Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Hum Pathol 1992;23:117-28.
82. Haller K, Stubenrauch F, Pfister H. Differentiation-dependent transcription of the epidermodysplasia verruciformis-associated human papillomavirus type 5 in benign lesions. Virology 1995;214:245-55.
83. Jablonska S, Orth G. Epidermodysplasia verruciformis. Clin Dermatol 1985;3:83-96.
84. Kreider JW, Howett MK, Wolfe SA, et al. Morphological transformation of human uterine cervix with papillomavirus from condylomata acuminata. Nature 1985;317: 639-41.
85. Howett MK, Christensen ND, Kreider JW. Tissue xenograft as a model system for study of the pathogenesis of papillomaviruses. Clin Dermatol 1997;15:229-36.
86. Sterling J, Stanley M, Gatward G, et al. Production of human papillomavirus type 16 virions in a keratinocyte cell line. J Virol 1990;64:6305-7.
87. Asselineau D, Bernard B, Bailly C, et al. Epidermal morphogenesis and induction of the 67 kD keratin polypeptide by culture of human keratinocytes at the liquid-air interface. Exp Cell Res 1985;159:536-9.
88. Meyers C, Frattini MG, Hudson JB, et al. Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation. Science 1992;257:971-3.
89. Dollard SC, Chow LT, Kreider JW, et al. Characterization of an HPV type 11 isolate propagated in human foreskin implants in nude mice. Virology 1989;171:294-7.
90. Chow LT, Broker TR. In vitro experimental systems for HPV: epithelial raft cultures for investigations of viral reproduction and pathogenesis and for genetic analyses of viral proteins and regulatory sequences. Clin Dermatol 1997;15:217-227.
91. Frattini MG, Lim HB, Laimins LA. In vitro synthesis of oncogenic human papillomaviruses requires episomal genomes for differentiation-dependent late expression. Proc Natl Acad Sci USA 1996;93:3062-7.
92. McDougall JK. HPV immortalisation and transformation. In: Lacey C, editor. Papillomavirus Reviews: Current research on Papillomaviruses. Leeds: Leeds University Press 1996:47-53.
93. Chen TM, Pecoraro G, Defendi V. Genetic analysis of in vitro progression of human papillomavirus-transfected human cervical cells. Cancer Res 1993;53:1167-71.
94. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human papillomaviruses. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. vol. 64. Lyon: International Agency for Research on Cancer, 1995.
95. De Villiers E-M. Papillomavirus detection and HPV typing. Clin Dermatol 1997;15:199-206.
96. Schiffman MH. New epidemiology of human papillomavirus infection and cervical neoplasia. J Nat Cancer Inst 1995;87:1345-7.
97. De Jong-Tieben LM, Berkhout RJM, Smits HL, et al. High frequency of detection of epidermodysplasia verruciformis-associated human papillomavirus DNA in biopsies from malignant and premalignant skin lesions from renal transplant recipients. J Invest Dermatol 1995;105:367-71.
98. Pfister H, ter Schegget J. Role of HPV in cutaneous premalignant and malignant tumors. Clin Dermatol 1997; 15(2): .
99. Bouwes Bavinck JN, Berkhout RJM. HPV infections and immunosuppression. Clin Dermatol 1997;15(2): .
100. Jablonska S, Majewski S, Obalek S, et al. Cutaneous warts. Clin Dermatol 1997 (in press).
101. Bergeron C, Barrasso R, Beaudenon S, et al. Human papillomaviruses associated with cervical intraepithelial neoplasia: Great diversity and distinct distribution in low-and high-grade lesions. Am J Surg Pathol 1992;16: 641-9.
102. Lörincz AT, Reid R, Jenson AB, et al. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol 1992;79: 328-37.
103. Grussendorf-Conen E-I. Anogenital premalignant and malignant tumors (including Buschke-Löwenstein tumors). Clin Dermatol 1997 (in press).
104. Bosch FX, Manos MM, Muñoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Nat Cancer Inst 1995;87:796-802.
105. Matsukura T, Sugase M. Identification of genital human papillomaviruses in cervical biopsy specimens: segregation of specific virus types in specific clinicopathologic lesions. Int J Cancer 1995;61:13-22.
106. Kienzler JL, Lemoine MT, Orth G, et al. Humoral and cell-mediated immunity to human papillomavirus type 1 (HPV-1) in human warts. Br J Dermatol 1983;108:665-72.
107. Steele JC, Gallimore PH. Humoral assays of human sera to disrupted and nondisrupted epitopes of human papillomavirus type 1. Virology 1990;174:388-98.
108. Christensen ND, Kreider JW, Shah KV, et al. Detection of human serum antibodies that neutralize infectious human papillomavirus type 11 virions. J Gen Virol 1992;73: 1261-7.
109. Kimbauer R, Hubbert NL, Wheeler CM, et al. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst 1994;86:494-9.
110. Heim K, Christensen ND, Hoepfl R, et al. Serum IgG, IgM, and IgA reactivity to human papillomavirus types 11 and 6 virus-like particles in different gynecologic patient groups. J Infect Dis 1995;172:395-402.
111. Carter JJ, Hagensee M, Taflin MC, et al. HPV-1 capsids expressed in vitro detect human serum antibodies associated with foot warts. Virology 1993;195:456-62.
112. Wideroff L, Schiffman MH, Nonnenmacher B, et al. Evaluation of seroreactivity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia. J Infect Dis 1995;172:1425-30.
113. Nonnenmacher B, Hubbert NL, Kimbauer R, et al. Serologic response to human papillomavirus type 16 (HPV-16) virus-like particles in HPV-16 DNA-positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Colombia and Spain. J Infect Dis 1995;172:19-24.
114. Dillner J, Kallings I, Brihmer C, et al. Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior. J Infect Dis 1996;173:1394-8.
115. Chua K-L, Wiklund F, Lenner P, et al. A prospective study on the risk of cervical intra-epithelial neoplasia among healthy subjects with serum antibodies to HPV compared with HPV DNA in cervical smears. Int J Cancer 1996;68:54-9.
116. Viscidi RP, Sun Y, Tsuzaki B, et al. Serologic response in human papillomavirus-associated invasive cervical cancer. Int J Cancer 1993;55:780-4.
117. Stern PL. Immunity to human papillomavirus-associated cervical neoplasia. In: Vandewoude GF, Klein G, editors. Advances in cancer research. vol. 69. San Diego: Academic Press, 1996:175-211.
118. Tagami H, Aiba S, Rokugo M. Regression of flat warts and common warts. Clin Dermatol 1985;3:170-8.
119. Coleman N, Birley HDL, Renton AM, et al. Immunological events in regressing genital warts. Am J Clin Pathol 1994;102:768-74.
120. Kast WM, Feltkamp MCW, Ressing ME, et al. Cellular immunity against human papillomavirus associated cervical cancer. Semin Virol 1996;7:117-23.
121. Malejczyk J, Majewski S, Jablonska S. The regulatory influence of immunological host responses. In: Gross G, von Krogh G, editors. Human papillomavirus infections in dermatovenereology. Boca Raton, New York, London, Tokyo: CRC Press, 1997;203-26.
122. Beaudenon S, Praetorius F, Kremdorf D, et al. A new type of human papillomavirus associated with oral focal epithelial hyperplasia. J Invest Dermatol 1987;88:130-35.
123. Praetorius F. HPV-associated diseases of oral mucosa. Clin Dermatol 1997 (in press).
124. Majewski S, Jablonska S, Orth G. Epidermodysplasia verruciformis as a model for HPV-related oncogenesis. In: Gross G, von Krogh G, editors. Human papillomavirus infections in dermatovenereology. Boca Raton, New York, London, Tokyo: CRC Press, 1997:131-50.
125. Majewski S, Jablonska S. Epidermodysplasia verruciformis. Immunological and nonimmunological surveillance mechanisms: role in tumor progression. Clin Dermatol 1997 (in press).
126. Wank R, Thomssen C. High risk of squamous cell carcinoma of the cervix for women with HLA-DQw3. Nature 1991;352:723-5.
127. Apple RJ, Becker TM, Wheeler CM, et al. Comparison of human leukocyte antigen DR-DQ disease associations found with cervical dysplasia and invasive cervical carcinoma. J Nat Cancer Inst 1995;87:427-36.
128. Odunsi K, Terry G, Ho L, et al. Susceptibility to human papillomavirus-associated cervical intra-epithelial neoplasia is determined by specific HLA DR-DQ alleles. Int J Cancer 1996;67:595-602.
129. Apple RJ, Erlich HA, Klitz W, et al. HLA DR-DQ associations with cervical carcinoma show papillomavirus-type specificity. Nature Genet 1994;6:157-62.
130. Ramoz N, Buée B, Jablonska S, et al. Specific HLA DR-DQ haplotypes linked to epidermodysplasia verruciformis. 1997; Submitted for publication.
131. Yabe Y, Tanimura Y, Sakai A, et al. Molecular characteristics and physical state of human papillomavirus DNA change with progressing malignancy: studies in a patient with epidermodysplasia verruciformis. Int J Cancer 1989; 43:1022-8.
132. Ostrow RS, Bender M, Niimura M, et al. Human papillomavirus DNA in cutaneous primary and metastasized squamous cell carcinomas from patients with epidermodysplasia verruciformis. Proc Natl Acad Sci USA 1982; 79:1634-8.
133. Lutzner M, Croissant O, Ducasse M-F, et al. A potentially oncogenic human papillomavirus (HPV-5) found in two renal allograft recipients. J Invest Dermatol 1980;75: 353-6.
134. Barr BBB, Benton EC, McLaren K, et al. Human papillomavirus infection and skin cancer in renal allograft recipients. Lancet 1989;i:124-9.
135. Lutzner MA, Orth G, Dutronquay V, et al. Detection of human papillomavirus type 5 DNA in skin cancers of an immunosuppressed renal allograft recipient. Lancet 1983;2:422-4.
136. Richart RM. Cervical intraepithelial neoplasia: a review. Pathol Annu 1973;8:301-28.
137. Koutsky LA, Holmes KK, Critchlow CW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992;327:1272-8.
138. Wright TC, Kurman RJ. A critical review of the morphologic classification systems of preinvasive lesions of the cervix: the scientific basis for shifting the paradigm. In: Lacey C, editor. Papillomavirus reviews: Current research on papillomaviruses. Leeds: Leeds University Press 1996:215-25.
139. Schiffman MH, Bauer HM, Hoover RN, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Nat Cancer Inst 1993;85:958-64.
140. Bosch FX, Muñoz N, de Sanjose S, et al. Risk factors for cervical cancer in Colombia and Spain. Int J Cancer 1992; 52:750-8.
141. Remmink AJ, Walboomers JMM, Heimerhorst TJM, et al. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer 1995;61:306-11.
142. Heino P, Eklund C, Frederiksson-Shanazarian V, et al. Association of serum immunoglobulin g antibodies against human papillomavirus type 16 capsids with anal epidermoid carcinoma. J Nat Cancer Inst 1995;87:437-40.
143. Von Knebel-Doeberitz M, Oltersdorf T, Schwarz E, et al. Correlation of modified human papilloma virus early gene expression with altered growth properties in C4-1 cervical carcinoma cells. Cancer Res 1988;48:3780-6.
144. Smits HL, Raadsheer E, Rood I, et al. Induction of anchorage-independent growth of human embryonic fibroblasts with a deletion in the short arm of chromosome 11 by human papillomavirus type 16 DNA. J Virol 1988;62: 4538-43.
145. Malejczyk J, Malejczyk M, Majewski S, et al. Increased tumorigenicity of human keratinocytes harboring human papillomavirus type 16 is associated with resistance to endogenous tumor necrosis factor-α-mediated growth limitation. Int J Cancer 1994;56:593-8.
146. Rösl F, Lengert M, Albrecht J, et al. Differential regulation of the JE gene encoding the monocyte chemoattractant protein (MCP-1) in cervical carcinoma cells and derived hybrids. J Virol 1994;68:2142-50.
147. Kyo S, Inoue M, Hayasaka N, et al. Regulation of early gene expression of human papillomavirus type 16 by inflammatory cytokines. Virology 1994;200:130-9.
148. Braun L, Dürst M, Mikumo R, et al. Regulation of growth and gene expression in human papillomavirus-transformed keratinocytes by transforming growth factor-β: implications for the control of papillomavirus infection. Mol Carcinog 1992;6:100-11.
149. Malejczyk J, Malejczyk M, Breitburd F, et al. Progressive growth of human papillomavirus type 16-transformed keratinocytes is associated with an increased release of soluble tumour necrosis factor (TNF) receptor. Br J Cancer 1996;74:234-9.
150. O'Connor MJ, Tan S-H, Tan C-H, et al. YY1 represses human papillomavirus type 16 transcription by quenching AP-1 activity. J Virol 1996;70:6529-39.
151. May M, Dong XP, Beyer-Finkler E, et al. The E6/E7 promoter of extrachromosomal HPV16 DNA in cervical cancers escapes from cellular repression by mutation of target sequences for YY1. EMBO J 1994;13:1460-6.
152. Cullen AP, Reid R, Campion M, et al. Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasm. J Virol 1991;65:606-12.
153. Heselmeyer K, Schröck E, du Manoir S, et al. Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix. Proc Natl Acad Sci USA 1996;93:479-84.
154. Mullokandov MR, Kholidilov NG, Atkin NB, et al. Genomic alterations in cervical carcinoma: losses of chromosome heterozygosity and human papilloma virus tumor status. Cancer Res 1996;56:197-205.
155. Ning Y, Weber JL, Killary DH, et al. Genetic analysis of indefinite division in human cells: evidence for a cell senescence-related gene(s) on human chromosome 4. Proc Natl Acad Sci USA 1991;88:5635-9.
156. Saxon PJ, Srivatsan ES, Stanbridge EJ. Introduction of human chromosome 11 via microcell transfer controls tumorigenic expression of HeLa cells. EMBO J 1986;5: 3461-6.
157. Sastre-Garau X, Couturier J, Favre M, et al. A recurrent human papillomavirus integration site at chromosome region 12q14-q15 in SW756 and SK-v cell lines derived from genital tumors. C R Acad Sci [III] 1995;318:475-8.
158. Couturier J, Sastre-Garau X, Schneider-Maunoury S, et al. Integration of papillomavirus DNA near myc genes in genital cancers and its consequences on proto-oncogene expression. J Virol 1991;65:4534-8.
159. Riou G, Favre M, Jeannel D, et al. Association between poor prognosis in early-stage invasive cervical carcinomas and non detection of HPV DNA. Lancet. 1990;335: 1171-4.
160. Snijders PJF, Steenbergen RDM, Meijer CJLM, et al. Role of human papillomaviruses in cancer of the respiratory and upper digestive tract. Clin Dermatol 1997;15.
161. Cox JT, Lörincz AT, Schiffman MH, et al. Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 1995;172:946-54.
162. Suzich JA, Ghim S-J, Palmer-Hill FJ, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 1995;92:11553-7.
163. Borysiewicz LK, Fiander A, Nimako M, et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet. 1996;347:1523-7.
164. Baker C, Calef C. Maps of papillomavirus mRNA transcripts. In: Myers G, Delius H, Icenogel J et al, editors. Human papillomaviruses 1995. A compilation and analysis of nucleic acid and amino acid sequences. Los Alamos: Los Alamos National Laboratory, 1995;III-3-III-20.